Overview


According to FutureWise analysis, the market for Blood Based Biomarker is expected to grow with a CAGR of 12.8% over the forecast period 2024-2032, and reach a market value of US$ 55.5 Billion by 2031. 

Blood-based biomarkers represent a revolutionary frontier in modern medicine, offering a non-invasive and easily accessible means to glean invaluable insights into an individual's health status, disease progression, and response to treatment. These biomarkers are specific molecules or cellular components in the blood, such as proteins, DNA, RNA, or metabolites, indicating various physiological or pathological processes occurring within the body.

Significant advantages of blood-based biomarkers lie in their potential to revolutionize early disease detection. By analyzing specific biomarkers associated with particular conditions, healthcare professionals can identify diseases at their nascent stages, when intervention and treatment are most effective. For instance, elevated levels of specific proteins like PSA (Prostate-Specific Antigen) can signal the presence of prostate cancer, enabling timely intervention. Moreover, blood-based biomarkers are pivotal in monitoring disease progression and treatment efficacy. Through repeated testing, clinicians can track changes in biomarker levels over time, providing crucial insights into how a disease evolves and how a patient responds to therapeutic interventions. This dynamic feedback loop allows for personalized treatment adjustments, optimizing patient outcomes.

FutureWise Market Research has published a report that provides an insightful analysis of Blood Based Biomarker Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Blood Based Biomarker Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Diadem srl.
  • Proteomedix
  • Cleveland Diagnostics
  • F. Hoffmann-La Roche Ltd
  • GENFIT
  • Nutech Cancer Biomarkers India Pvt Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

On the driver side, continuous advancements in genomics, proteomics, and metabolomics technologies have significantly expanded our understanding of blood-based biomarkers. This has led to the discovery of novel biomarkers and their potential applications in various diseases. The shift towards personalized medicine, tailoring treatments to individual patient characteristics, drives the demand for blood-based biomarkers. These biomarkers are crucial in identifying specific genetic, molecular, and metabolic profiles that inform treatment decisions. The rising surge of chronic ailments, such as cancer, cardiovascular disorders, and neurodegenerative conditions, necessitates developing and utilizing blood-based biomarkers for early detection, prognosis, and monitoring of these conditions. The ability of blood-based biomarkers to detect diseases at an early stage, when intervention is most effective, is a significant driver. Early detection can improve outcomes, reduce treatment costs, and improve patient survival rates.

However, there are significant restraints for the market; ensuring the accuracy, reproducibility, and standardization of biomarker assays across different laboratories and platforms can be complex. Validation studies and standardization efforts are essential but may present logistical and scientific challenges. Blood-based biomarkers raise ethical concerns regarding patient privacy, consent, and the responsible use of genetic and molecular information. Regulatory compliance with data protection laws and ethical guidelines is crucial, hampering the market growth.

By Type

  • Screening Biomarker
  • Diagnosis Biomarker
  • Others

By Disease

  • Cancer
  • Neurological Disorders
  • Others

By Application

  • Diagnostics
  • Drug Discovery
  • Personalized Medicine

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to robust healthcare infrastructure, the prominent presence of key industry players, a surge in chronic ailments, and heightened research endeavors in this geographical region. 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Blood Based Biomarker Market By Type, By Disease, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction

    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology

    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary

    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Blood Based Biomarker Market Variables, Trends & Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview

    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Blood Based Biomarker Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Blood Based Biomarker Market Analysis Tools

    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Blood Based Biomarker Market, By Type Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Screening Biomarker
        2. Diagnosis Biomarker
        3. Others

  • 8.  Blood Based Biomarker Market, By Disease Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Cancer
        2. Neurological Disorders
        3. Others

  • 9.  Blood Based Biomarker Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Diagnostics
        2. Drug Discovery
        3. Personalized Medicine

  • 10.  North America Blood Based Biomarker Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Blood Based Biomarker Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Blood Based Biomarker Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Blood Based Biomarker Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Diadem srl.
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Proteomedix
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Cleveland Diagnostics
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. F. Hoffmann-La Roche Ltd
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. GENFIT
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Nutech Cancer Biomarkers India Pvt Ltd.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client

    • .


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11